Apollon Wealth Management LLC Sells 146 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Apollon Wealth Management LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,348 shares of the biopharmaceutical company’s stock after selling 146 shares during the quarter. Apollon Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,758,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Kingswood Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company’s stock worth $681,000 after buying an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV grew its stake in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 19 shares during the period. Private Trust Co. NA grew its stake in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 19 shares during the period. Proficio Capital Partners LLC grew its stake in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 19 shares during the period. Finally, Cove Private Wealth LLC grew its stake in Regeneron Pharmaceuticals by 4.5% in the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 20 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on REGN shares. Citigroup upped their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research note on Monday. Sanford C. Bernstein upped their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $817.88.

Regeneron Pharmaceuticals Stock Down 1.2%

REGN stock opened at $557.73 on Tuesday. The stock has a fifty day moving average of $573.67 and a 200-day moving average of $563.46. The company has a market capitalization of $59.11 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.56 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.